Plain-English translation of NCT06957886 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is comparing a new drug called to standard chemotherapy treatments in women with advanced breast cancer that has spread or come back. is given as an intravenous infusion (through your vein) every 3 weeks. Researchers want to see if this medication works better and is safer than the chemotherapy options doctors typically use for this type of cancer.
Some breast cancers have low levels of a protein called HER2, and these cancers can be harder to treat with existing therapies. This trial exists to see if this new medication might be a better option for patients with this specific type of advanced breast cancer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication or one of several standard chemotherapy drugs. You will receive your treatment as an intravenous infusion every 3 weeks, and you can continue receiving it as long as it is helping and you are tolerating it well. Your doctor will monitor you closely with blood tests and imaging scans to see how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China